Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.51 USD | -0.94% | -5.46% | -4.94% |
May. 23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
May. 23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.94% | 1.51B | |
+16.41% | 79.16B | |
+8.35% | 8.72B | |
-16.83% | 4.79B | |
+47.36% | 4.62B | |
+1.74% | 3.82B | |
+14.51% | 2.33B | |
-26.23% | 2.2B | |
+15.63% | 2.1B | |
-34.87% | 2.04B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Piper Sandler Cuts Price Target on Supernus Pharmaceuticals to $41 From $45, Maintains Overweight Rating